Background: Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDLcholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality.
Introduction
At present three canonical genes underlie familial hypercholesterolemia (FH) with co-dominant transmission (autosomal dominant hypercholesterolemia, ADH): LDLR (ADH-type 1), APOB (ADH-type 2) and PCSK9 (ADHtype 3). Other genes, like STAP1 (ADH-type 4) and APOE (ADH-type 5) have been implicated in some rare forms of FH with dominant transmission [1e3] . In all molecular surveys performed so far in different cohorts of FH patients, mutations in LDLR gene were found in more than 85e90% of FH cases. More than 1700 mutations of this gene have been reported so far and annotated in the UCL database [4] . Few mutations in APOB underlie ADH-2, two of which are predominant [5] . Gain-of-function (GOF) mutations of PCSK9 causing FH are exceedingly rare [6] . Only a single mutation in APOE gene [p.(Leu167del)] was found to be the cause of a dominant FH phenotype [3] . FH-like phenotypes with a recessive transmission are extremely rare. This group of disorders includes the classic autosomal recessive hypercholesterolemia (ARH) caused by mutations in LDLRAP1 gene [7] , sitosterolemia caused by mutations in ABCG5/ABCG8 genes [8] , and lysosomal acid lipase deficiency (LAL-D) due to mutations in LIPA gene [9] .
With regard to the prevalence of FH with co-dominant transmission (ADH), recent data based on the determination of the carrier status of pathogenic variants in LDLR and APOB genes indicate a frequency of 1:217 for heterozygotes in the general population [10] . An extensive molecular study conducted in the Netherlands in genotyped FH patients indicated a prevalence of heterozygous ADH of 1:244 individuals and a prevalence of homozygous FH of 1:300,000 [11] . Several reports have shown that a variable percentage (20e40%) of patients with the clinical diagnosis of heterozygous FH do not carry mutations in the candidate genes mentioned above [12] . Some of these patients were found to carry a burden of LDL-cholesterol (LDL-C) increasing gene variants which cumulatively raise LDL-C levels into the heterozygous FH range [12, 13] . However, there are patients in whom the polygenic effect does not explain the high LDL-C levels, indicating the possible presence of other genes yet to be identified [13] .
In a previous study [14] we have characterized the molecular bases of ADH in a cohort of Italian FH patients attending three Lipid Clinics in Italy and performed a systematic analysis of the clinical features of mutationpositive ADH patients. This study paved the way for the construction of the LIPIGEN network, as an integrated network aimed at the early clinical/molecular identification and treatment of patients with genetic dyslipidemias (Ref. Averna M. et al. in this issue). The first aim of LIPIGEN was to improve the identification and molecular characterization of FH patients thanks to a collaboration among a large number of Lipid Clinics distributed over the entire country. In this brief report we show the results of the molecular characterization of more than 1000 patients carried out during the first two years of activity of the LIPIGEN network.
Materials and methods

Subjects
For this analysis, 1592 unrelated patients from 20 outpatient clinics with clinical diagnosis of FH and a Dutch Lipid Clinic Network (DLCN) score 6 were genetically tested for the presence of variants in FH causing genes. Informed consent was obtained from all subjects. The project was approved by the Ethics Committees of each participating institution.
DNA isolation and sequencing
Genomic DNA was extracted using the Flexigene DNA kit (Qiagen, Milan, Italy) according to the manufacturer's instructions. Appropriate primers were used for the PCR amplification of exons and exon-intron junctions of the following genes: LDLR (18 exons), PCSK9 (12 exons) and LDLRAP1 (9 exons), as well as regions in APOB exons 26 and 29 involved in the binding to LDLR, exon 4 of APOE gene and STAP1 gene (9 exons). As internal control, regions of chromosome 21 were amplified. Fifty-eight regions of interest (20 Kb) were amplified from genomic DNA in five different multiplex PCR reactions. A second amplification was then performed in order to include an 8nt index sequence used for sample identification, as well as the adaptors used for sequencing on MiSeq (Illumina) equipment. Before sequencing, purified amplified samples were quantified and diluted to the same concentration. The genetic analysis, including the complete sequence of genes, was performed by Next Generation Sequencing (see above) followed by the Sanger sequence to confirm the presence of the identified variant. Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was used to detect copy number variations.
In silico analysis of missense mutations was performed using PolyPhen-2 HumDiv and Hum Var (http://genetics. bwh.harvard.edu/pph2/), SIFT Human Protein (http://sift. jcvi.org/) and Mutation Taster (www.mutationtaster.org/). The potential effect of an intronic variant on pre-mRNA splicing was assessed by Human Splicing Finder (http:// www.umd.be/HSF3/HSF.html), NetGene2 (http://www.cbs. dtu.dk/sevices/NetGene2/), BDGP Splice Site prediction (http://www.fruitfly.org/seq_tools/splice.html), Splice Port (http://spliceport.cbcb.umd.edu/) and Splice Site Score Calculation (http://rulai.cshl.edu/new_alt_exon_db2/HTML/ score.html).
Results
In a series of 1592 FH index subjects, 1076 (67.6%) were found to carry at least one variant of the investigated genes. Most of them (1016 subjects, 94.4%) carried at least one variant in the LDLR gene; a total number of 213 variants of LDLR gene have been identified. More than 90% of patients were carriers of definite pathogenic/likely pathogenic LDLR gene variants. Most LDLR variants were single nucleotide substitutions, mainly in the coding sequence. Large gene deletions were found in 53 subjects, whereas single nucleotide or minute deletions were found in 36 and 45 subjects respectively. Single nucleotide or minute duplications were found in 21 subjects.
The most common mutations in LDLR gene were [c.1646G>A, p. (Gly549Asp) [14] . Thirty-two LDLR gene variants found in this survey had not been reported previously. In silico analysis indicated that 27 of them could be regarded as pathogenic/likely pathogenic variants (Table 1) .
Pathogenic APOB gene variants located in exon 26 (Table 2) were found in 34 subjects.
Four PCSK9 variants were found in 36 subjects (Table  3 ). The most common were: i) the [c.137G>T, p.(Arg46Leu)] variant (found in 15 subjects), which is a known loss-of-function variant (LOF) associated with reduced LDL-C levels, and ii) c.60_65dupGCTGCT [p.(Leu21tri)] (in 17 subjects), which is regarded to be a GOF variant and a possible cause of FH [6] .
Twelve LDLRAP1 gene variants were identified in 18 subjects. Five variants were pathogenic, 4 unlikely pathogenic and 3 of unknown significance (Table 4) . Among the identified LDLRAP1 variants, 4 have not been reported previously. However, only 1 of these new variants can be assumed to be pathogenic. We found 17 subjects carrying two variants in LDLR gene (Table 5 ). Only 8 of these subjects carried five combinations of two variants with pathogenic effect. No formal family study was performed to assess whether the two variants were on the same or on different alleles. However it can be reasonable assumed that carriers of two pathogenic variants (8 patients) might be compound heterozygotes.
Nineteen subjects were double heterozygotes for LDLR/ PCSK9 variants (Table 6 ). However only seven of these subjects were found to carry a putative or definite GOF variant of PCSK9 expected to contribute to the FH phenotype. Five subjects were double heterozygotes for pathogenic variants of LDLR and APOB genes ( Table 7) .
We also identified 5 double heterozygotes for LDLR/ LDLRAP1 variants; all of them carried a pathogenic variant in LDLR gene, but only one was carrier of a pathogenic variant of LDLRAP1 gene (Table 8) .
Seven true homozygous patients were detected; 5 of them were homozygous for LDLR gene variants and 2 for LDLRAP1 gene variants. (Table 9) .
Finally, one subject was found to carry the APOE gene variant c.500_502delTCC [p. (Leu167del) ], known to be associated with a dominant FH phenotype.
Discussion
In this preliminary report we describe the molecular findings in 1592 patients suspected to have definite or probable familial hypercholesterolemia identified through a national collaborative detection program. Only patients with a Dutch score 6 were admitted to the molecular investigation program. The exclusion of patients with In silico analysis of missense mutations was performed using PolyPhen-2 HumDiv and Hum Var (http://genetics.bwh.harvard.edu/pph2/), SIFT Human Protein (http://sift.jcvi.org/) and Mutation Taster (www.mutationtaster.org). Table 7 Double heterozygotes for LDLR and APOB gene variants. [11] was due to funding limitations, organization problems and to the deliberate intent to concentrate our efforts on patients who are more likely to have a monogenic disorder. We used targeted next generation sequencing which allowed the parallel sequencing of the major genes known to be responsible for monogenic forms of hypercholesterolemia.
The overall detection rate of pathogenic/likely pathogenic variants was around 60%, a figure which is comparable to that obtained in other studies [12, 13] . The assignment of pathogenicity was based on in silico analysis using several algorithms [4] and information available in the published variant databases.
In accordance with findings from our previous study [14] , more than 90% of variant-positive patients were carriers of pathogenic or likely pathogenic variants in the LDLR gene. Among these patients we discovered 4 true FH homozygotes carrying known pathogenic variants and 5 patients likely be to be compound heterozygotes (as they were carriers of two known pathogenic or likely pathogenic variants of LDLR gene). In this survey we discovered 32 LDLR gene variants not reported previously in FH patients. A stringent in silico analysis [15] indicated that most of these variants can be assumed to be pathogenic or likely pathogenic.
As previously observed [14] , only few patients were found to be heterozygous carriers of one of the three known APOB pathogenic variants. None of the patients was found to be homozygous/compound heterozygous for any of these variants. However some patients resulted to be double heterozygous for pathogenic LDLR/APOB variants. Overall, these findings confirm that APOB variants are a rare cause of FH in Italy.
Few patients were found to be heterozygous for putative pathogenic GOF variants of PCSK9 gene. Surprisingly, none of them carried one of the three GOF variants reported previously in Italian FH patients [14] or one of those reported in a recent large survey of FH patients carrying PCSK9 variants [16] . As a matter of fact, a convincing demonstration of pathogenicity of one putative GOF variant found in our FH patients [c.60_65dupGCTGCT (c.61_63triCTG), p. (Leu21tri)] is not yet available. The same caution applies also to patients found to be double heterozygotes for LDLR and PCSK9 variants (Table 6) . Interestingly, most of these double heterozygous patients (carrying LDLR pathogenic variants) were found to carry the common polymorphic p.(Arg46Leu) variant, which is known to have an LDL-C lowering effect in normolipidemic as well as in FH patients [17e19] .
We sequenced also the LDLRAP1 gene whose pathogenic variants are the cause of autosomal recessive hypercholesterolemia (ARH), an exceedingly rare disorder in most countries with exception of the Italian island of Sardinia [7] . Two patients of our series were found to have ARH due to pathogenic variants of LDLRAP1 while one patient was found to be double heterozygous for LDLR and LDLRAP1 pathogenic variants.
This survey included also the sequence of APOE gene, in the light of previous studies suggesting that some rare apoE variants might be associated with an FH-like phenotype. We found only one patient heterozygous for a known apoE variant [p.(Leu167del)], considered the cause of FH with dominant transmission [3] . Recently a large study conducted in 228 Spanish FH patients in whom the LDLR, APOB and PCSK9 pathogenic variants had been excluded, showed that nine patients (3.1%) were carriers of the p.(Leu167del) variant [20] . This variant was found to segregate with FH phenotype among index cases' family members. In view of these findings, APOE gene should be included among the genes responsible for FH [21] .
This molecular survey paves the way to two main actions: i) a deep phenotypic analysis of the molecularly characterized patients, including response to treatment with hypolipidemic drugs; ii) implementation of the cascade screening of index patients' family members to identify carriers of pathogenic variants and characterize their phenotype. In view of our previous study, the cascade screening is expected to lead to the identification of at least 2000 carriers of pathogenic variants who may be unaware of the burden of having high LDL-C from birth and may benefit from early treatment and genetic counselling. 
